Your browser doesn't support javascript.
loading
Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia.
Assayag, Deborah; Adegunsoye, Ayodeji; Sheehy, Robert; Morisset, Julie; Khalil, Nasreen; Johannson, Kerri A; Marcoux, Veronica; Kolb, Martin; Fisher, Jolene H; Manganas, Helene; Wrobel, Jeremy; Wilsher, Margaret; De Boer, Sally; Mackintosh, John; Chambers, Daniel C; Glaspole, Ian; Keir, Gregory J; Lee, Cathryn T; Jablonski, Renea; Vij, Rekha; Strek, Mary E; Corte, Tamera J; Ryerson, Christopher J.
Afiliação
  • Assayag D; Department of Medicine, McGill University, Montreal, QC, Canada. Electronic address: deborah.assayag@mcgill.ca.
  • Adegunsoye A; Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL.
  • Sheehy R; Department of Respiratory Medicine, Princess Alexandra Hospital and University of Queensland, Brisbane, QLD, Australia.
  • Morisset J; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Khalil N; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Johannson KA; Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Marcoux V; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Kolb M; Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.
  • Fisher JH; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Manganas H; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
  • Wrobel J; Advanced Lung Disease Unit, Fiona Stanley Hospital, Perth, WA, Australia and University of Notre Dame Fremantle, Fremantle, WA, Australia.
  • Wilsher M; Respiratory Services, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
  • De Boer S; Respiratory Services, Auckland City Hospital and University of Auckland, Auckland, New Zealand.
  • Mackintosh J; Department of Thoracic Medicine, Prince Charles Hospital and University of Queensland, Brisbane, QLD, Australia.
  • Chambers DC; Department of Thoracic Medicine, Prince Charles Hospital and University of Queensland, Brisbane, QLD, Australia.
  • Glaspole I; Department of Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia.
  • Keir GJ; Department of Respiratory Medicine, Princess Alexandra Hospital and University of Queensland, Brisbane, QLD, Australia.
  • Lee CT; Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL.
  • Jablonski R; Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL.
  • Vij R; Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL.
  • Strek ME; Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, IL.
  • Corte TJ; Department of Respiratory Medicine, Royal Prince Alfred Hospital, and University of Sydney, Sydney, NSW, Australia.
  • Ryerson CJ; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Chest ; 163(5): 1156-1165, 2023 05.
Article em En | MEDLINE | ID: mdl-36621759
BACKGROUND: Biological sex, gender, and race are important considerations in patients with interstitial lung diseases (ILDs). RESEARCH QUESTION: Does a patient's sex assigned at birth, and race, influence ILD treatment initiation? STUDY DESIGN AND METHODS: Patients with ILD from three longitudinal prospective registries were compared in this observational study. ILD-related medications included antifibrotics and immunomodulating medications. Race was dichotomized as "White" vs "non-White." Time to treatment initiation was determined from the date of the initial ILD registry visit to the date of first medication initiation. Proportions of treated patients were compared between groups by χ2 test. Cox proportional analysis was used to determine how sex and race were associated with time to treatment initiation stratified by ILD diagnosis. RESULTS: A total of 4,572 patients were included across all cohorts. The proportion of men who received treatment was higher than for women in the Canadian cohort (47% vs 40%; P < .001), and the proportion of White patients who received treatment was also higher compared with non-White patients (46% vs 36%; P < .001). In contrast, the proportion of treated men in the Chicago cohort was lower compared with women (56% vs 64%; P = .005), and that of White patients was lower compared with non-White patients (56% vs 69%; P < .001). No sex- or race-based differences in proportions of patients treated were found in the Australasian cohort. White race was significantly associated with earlier treatment initiation compared with non-White race across diagnoses in the Canadian cohort, whereas the opposite association was found in the Australasian cohort. INTERPRETATION: Sex- and race-based differences exist in the initiation of ILD treatment, with variability across different cohorts in different countries. Reasons for these differences need to be further explored in future studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Observational_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Limite: Female / Humans / Male / Newborn País/Região como assunto: America do norte / Oceania Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Tipo de estudo: Observational_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Limite: Female / Humans / Male / Newborn País/Região como assunto: America do norte / Oceania Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article
...